DC-FEELM
29.9.2022 14:46:40 CEST | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won the Golden Leaf Award for "Most Promising Innovation" at the 2022 Global Tobacco and Nicotine Forum (GTNF) in Washington, DC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005491/en/
GTNF event site (Photo: Business Wire)
“Using FEELM’s updated ceramic coil technology, the FEELM Max offers improved flavor consistency, more puffs and reduced harshness through smaller aerosol particles. Most importantly, the FEELM Max offers greater potential for harm reduction,” the organizer of GTNF announced at the award ceremony.
Four years ago, FEELM tech won the Golden Leaf Award. And four years later, FEELM Max won the Golden Leaf Award again, it is also FEELM Max's second global award this year after winning the Red Dot Award.
The Golden Leaf Award is one of the most prestigious awards in the sector and is designed to recognize companies and brands that have made outstanding contributions to the global tobacco and nicotine industry. The "Most Promising Innovation" award was open to companies that are launching new technologies and products, and was judged based on design innovation and projected future production efficiencies.
Speaking at the award ceremony, Chief Scientist of SMOORE American Research Institute, Dr. Shi, said:
"We have a long and extensive portfolio of breakthrough technologies to enhance the product experience, and we are delighted that FEELM Max has won, and our efforts have been recognized by global industry experts."
Today's new award represents another milestone in the continuing evolution of FEELM technology. With new materials, microstructures and processes, the FEELM Max technology sets a new bar in even more harm reduction and product performance improvement. It embodies the mission of the parent company Smoore International: innovation for better well-being, which ties well with the theme of this conference "Science, technology and innovation driving transformation."
According to the evaluation of industry experts, the technology within FEELM Max has the potential to bring the quality associated with reusable vaping products into the disposable market. As the world's first disposable atomization solution with a ceramic core, FEELM Max relies on its underlying technological innovation to surpass the traditional cotton core solution. It provides disposable products with "better taste, more puff, and higher consistency."
FEELM's single-use solutions are now sold in countries around the world, including in major economies like the United States, United Kingdom. SMOORE's interim financial report for 2022 showed that the revenue of disposable products in the first half of the year reached 319 million yuan, up 234.5 percent from the same period last year.
In addition to redefining products with technological innovation and creating a better vaping experience, FEELM Max also aims to have a lower carbon footprint than comparable products by introducing a series of green and sustainable technical solutions covering packaging, materials, and production.
The 2020 and 2021 GTNF awards had been postponed to 2022 due to the COVID-19 pandemic, which meant the competition was more intense than ever. The winners represented the innovations in the industry over the past three years, making FEELM even more proud to have won this award.
ENDS
For more information or journalist queries, please contact Tommy Gilchrist on 0044 7388 110 679 or via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
